173 related articles for article (PubMed ID: 32256484)
1. Immunogenicity and Immune Silence in Human Cancer.
Yarmarkovich M; Farrel A; Sison A; di Marco M; Raman P; Parris JL; Monos D; Lee H; Stevanovic S; Maris JM
Front Immunol; 2020; 11():69. PubMed ID: 32256484
[TBL] [Abstract][Full Text] [Related]
2. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
3. Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.
Claeys A; Luijts T; Marchal K; Van den Eynden J
PLoS Genet; 2021 Feb; 17(2):e1009368. PubMed ID: 33556087
[TBL] [Abstract][Full Text] [Related]
4. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
Sci China Life Sci; 2021 Dec; 64(12):2144-2152. PubMed ID: 33740187
[TBL] [Abstract][Full Text] [Related]
5. Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes.
Castro A; Ozturk K; Pyke RM; Xian S; Zanetti M; Carter H
BMC Med Genomics; 2019 Jul; 12(Suppl 6):107. PubMed ID: 31345234
[TBL] [Abstract][Full Text] [Related]
6. Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories.
Mizuno S; Yamaguchi R; Hasegawa T; Hayashi S; Fujita M; Zhang F; Koh Y; Lee SY; Yoon SS; Shimizu E; Komura M; Fujimoto A; Nagai M; Kato M; Liang H; Miyano S; Zhang Z; Nakagawa H; Imoto S
Sci Rep; 2021 Aug; 11(1):15713. PubMed ID: 34344966
[TBL] [Abstract][Full Text] [Related]
7. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
8. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune Evasion.
Gong X; Karchin R
Mol Cancer Res; 2022 Aug; 20(8):1272-1283. PubMed ID: 35533264
[TBL] [Abstract][Full Text] [Related]
10. Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos D; Zappasodi R; Schulze I; Sethna Z; de Andrade KC; Bajorin DF; Bandlamudi C; Callahan MK; Funt SA; Hadrup SR; Holm JS; Rosenberg JE; Shah SP; Vázquez-García I; Weigelt B; Wu M; Zamarin D; Campitelli LF; Osborne EJ; Klinger M; Robins HS; Khincha PP; Savage SA; Balachandran VP; Wolchok JD; Hellmann MD; Merghoub T; Levine AJ; Łuksza M; Greenbaum BD
Nature; 2022 Jun; 606(7912):172-179. PubMed ID: 35545680
[TBL] [Abstract][Full Text] [Related]
11. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
12. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
13. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
[TBL] [Abstract][Full Text] [Related]
14. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
15. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
Hicklin DJ; Marincola FM; Ferrone S
Mol Med Today; 1999 Apr; 5(4):178-86. PubMed ID: 10203751
[TBL] [Abstract][Full Text] [Related]
16. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
17. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
18. No evidence that HLA genotype influences the driver mutations that occur in cancer patients.
Kherreh N; Cleary S; Seoighe C
Cancer Immunol Immunother; 2022 Apr; 71(4):819-827. PubMed ID: 34417841
[TBL] [Abstract][Full Text] [Related]
19. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
20. Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico.
Soto-Nava M; Avila-Ríos S; Valenzuela-Ponce H; García-Morales C; Carlson JM; Tapia-Trejo D; Garrido-Rodriguez D; Alva-Hernández SN; García-Tellez TA; Murakami-Ogasawara A; ; Mallal SA; John M; Brockman MA; Brumme CJ; Brumme ZL; Reyes-Teran G;
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
